Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (EXIST-1)
This study has been completed.
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00789828
First received: November 12, 2008
Last updated: January 4, 2016
Last verified: January 2016
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: March 1, 2012
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
| Conditions: |
Tuberous Sclerosis Subependymal Giant Cell Astrocytoma |
| Interventions: |
Drug: Everolimus Drug: Placebo |
Participant Flow
Hide Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| The study was conducted at 24 centers in 10 countries. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| A total of 117 participants were enrolled and randomized into the core period. Only 111 participants completing the core period, continued in the open-label extension period of the study. |
Reporting Groups
| Description | |
|---|---|
| Everolimus | Participants received oral dose of everolimus 4.5 milligram/square meter (mg/m^2) daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 nanogram/millilitre (ng/mL). Dose adjustments were permitted based on safety and whole blood trough concentrations. |
| Placebo | Participants received oral dose of placebo matching to everolimus daily. |
Participant Flow for 2 periods
Period 1: Core Period (48 Weeks)
| Everolimus | Placebo | |
|---|---|---|
| STARTED | 78 | 39 |
| COMPLETED | 78 | 33 |
| NOT COMPLETED | 0 | 6 |
| Administrative problems | 0 | 1 |
| Withdrawal by Subject | 0 | 4 |
| Lost to Follow-up | 0 | 1 |
Period 2: Open-label Extension Period (4 Years)
| Everolimus | Placebo | |
|---|---|---|
| STARTED | 111 [1] | 0 [2] |
| COMPLETED | 82 | 0 |
| NOT COMPLETED | 29 | 0 |
| Adverse Event | 10 | 0 |
| Withdrawal by Subject | 6 | 0 |
| Lost to Follow-up | 3 | 0 |
| Administrative problems | 7 | 0 |
| Death | 1 | 0 |
| Disease progression | 1 | 0 |
| New treatment for indication under study | 1 | 0 |
| [1] | Of 117 participants only 111 completed the core period and continued in the extension period |
|---|---|
| [2] | No participant received placebo. |
Baseline Characteristics
Population Description
| Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. |
|---|
| No text entered. |
Reporting Groups
| Description | |
|---|---|
| Everolimus (Core Period) | Participants received oral dose of everolimus 4.5 mg/m^2 daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations. |
| Placebo (Core Period) | Participants received oral dose of placebo matching to everolimus daily. |
| Total | Total of all reporting groups |
Baseline Measures
| Everolimus (Core Period) | Placebo (Core Period) | Total | |
|---|---|---|---|
|
Number of Participants
[units: participants] |
78 | 39 | 117 |
|
Age
[units: years] Mean (Standard Deviation) |
10.1 (5.9) | 10.3 (7.3) | 10.2 (6.4) |
|
Age, Customized
[units: Participants] |
|||
| <3 years | 13 | 7 | 20 |
| 3-18 years | 55 | 26 | 81 |
| ≥18 years | 10 | 6 | 16 |
|
Gender
[units: participants] |
|||
| Female | 29 | 21 | 50 |
| Male | 49 | 18 | 67 |
Outcome Measures
Show All Outcome Measures
| 1. Primary: | Percentage of Participants With Best Overall Subependymal Giant Cell Astrocytomas (SEGA) Response [ Time Frame: End of core period (Week 48), and end of extension period (up to 4 years) ] |
| 2. Secondary: | Change From Baseline in Frequency of Total Seizure Events Per 24 Hours at Week 24 in Both Core and Extension Period [ Time Frame: Baseline (Core period) to Week 24 (Core period), Baseline (Extension period, Week 24 post-core baseline) to Week 24 (Extension period, Week 48 post-core baseline) ] |
| 3. Secondary: | Time to SEGA Progression [ Time Frame: Baseline up to week 48 (end of core period), and end of extension period (up to 4 years) ] |
| 4. Secondary: | Time to SEGA Response [ Time Frame: Baseline up to week 48 (end of core period), and end of extension period (up to 4 years) ] |
| 5. Secondary: | Duration of SEGA Response [ Time Frame: Baseline up to week 48 (end of core period), and end of extension period (up to 4 years) ] |
| 6. Secondary: | Time to SEGA Worsening [ Time Frame: Baseline up to week 48 (end of core period), and end of extension period (up to 4 years) ] |
| 7. Secondary: | Percentage of Participants With Skin Lesions Assessed Using Physician's Global Assessement Overall Score [ Time Frame: End of core period (Week 48), and end of extension period (up to 4 years) ] |
| 8. Secondary: | Duration of Skin Lesion Response in Everolimus Treated Participants [ Time Frame: Baseline up to week 48 (end of core period), and end of extension period (up to 4 years) ] |
| 9. Secondary: | Everolimus Blood Concentration (C2h) at 2 Hours Post Dose [ Time Frame: 2 hours post dose on Week 6, Week 24, Week 48, Week 96, Week 144, and Week 240 ] |
| 10. Secondary: | Everolimus Trough Concentrations (Cmin) at 24 Hours After Last Dose [ Time Frame: 24 hours post dose on Week 6, Week 24, Week 48, Week 72, Week 96, Week 144, and Week 240 ] |
| 11. Secondary: | Percentage of Participants With Renal Impairment During Core Period [ Time Frame: Day 1 up to 28 days after end of treatment (Core period) ] |
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |